In This Section

2017 ADDC Save the Date 

The focus of the second collaboration between ASPET and the Academic Drug Discovery Consortium (ADDC) will explore a critical domain to innovation – how to obtain funding.

Day one of the symposium will focus on successful translational programs funded through State, Federal, and International programs. Day two will be a unique opportunity to talk to translational Program Directors (see list). We hope you will leave the meeting both with inspiration and a concrete path forward.

Pharmaceutical companies have steadily decreased their research ranks for years. Recognizing a potential crisis in the making, governments have responded to the evolving R&D landscape by creating new mechanisms to fund research focused on identifying novel therapies for untreated patients. This phenomenon has occurred on a national scale and at the level of individual states and even some metropolitan regions now have funding instruments. A single investment can trigger the invention of a new treatment, support the education of the next generation of scientists and build economies in meaningful and lasting ways.

If you are interested in academic drug discovery and would like to build your network of collaborators, learn firsthand how other scientists have successfully developed their programs and explore the funding options available to launch and sustain a treatment discovery program, you will want to attend.

Abstract submission deadline:  Friday, July 21, 2017
Advance registration deadline:  Thursday, September 28, 2017

Register Now


Colloquium Registration Rates

On or before
Sept. 28

On or after
Sept. 29

Member of ADDC or ASPET



Non-member (non-profit)



Non-member (for-profit)



Trainees (student/postdoc)



Federal Employee Registration Only



Federal Employee Registration and Meals



Registration Fees Include

Colloquium registration fees include access to all keynotes, scientific talks, and poster sessions as well as all food functions listed in the final Colloquium schedule.  Colloquium pre-registrants will be given unlimited access to make appointments for the Friday partnering sessions.

The last day to register for the Colloquium is Wednesday, October 11, 2017 at 4:00 pm. Registrations after this that will be done on-site.

*No government funds will be used to purchase meals/refreshments at this event. 

Cancellation Policy

All registration fees are non-refundable.

Special Accommodations

Please contact us at or (301) 634-7060 if you require any special accommodations related to the Americans with Disabilities Act.

Organizers and Hosts

Colloquium Organizers

Michael W. Wood, PhD
Neupharm LLC
Program Committee Chair, ASPET

Janet Clark, PhD
Director for Fellowship Training, National Institute of Mental Health
National Institutes of Health

Michelle Arkin, PhD
University of California, San Francisco, School of Pharmacy
President, Academic Drug Discovery Consortium

Stephen Frye, PhD
University of North Carolina-Chapel Hill, Eshelman School of Pharmacy
Vice President, Academic Drug Discovery Consortium

*No government funds will be used to purchase meals/refreshments at this event. 

Colloquium Hosts


 ADDC Logo 

Program and Abstracts


Thursday, October 12

8:00 am – 9:00 am
Registration & Continental Breakfast

9:00 am – 9:05 am

Welcome Remarks

9:05 am – 9:50 am
KEYNOTE: Carlos Zarate, NIMH
“Experimental Therapeutics for Treatment-Resistant Depression”

9:50 am – 10:40 am
Donna Huryn, University of Pittsburgh
“p97 Allosteric Inhibitors: Partnership with the Chemical Biology Consortium”

Sriram Subramaniam, Center for Cancer Research, NIH

“Frontiers in Cryo-EM”

10:40 am – 10:55 am

Refreshment Break

10:55 am – 12:05 pm
Julian Blagg, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.

“Funding Cancer Drug Discovery in the United Kingdom”

Chuck Cywin, NINDS

“First in Man: Advancing Small Molecule Academic Drug Discovery Research through the Blueprint Neurotherapeutics Network”

Ann Mills-Duggan, Wellcome Trust

“Seeding Drug Discovery – What Next?”

12:05 pm – 12:15 pm
Ben Glasspoole, MilliporeSigma

“New Additions to the MedChem Toolbox from Academic Collaborations”

12:15 pm – 1:15 pm

Boxed Lunch with Poster Presentations

1:15 pm – 2:45 pm
Amy Newman, NIDA

“Translating the Dopamine D3 Receptor Hypothesis Toward Treatment of Opioid Use Disorders”

Jim Wells, University of California, San Francisco

“Antibodies Targeting the Cell Surfaceome”

Duncan Holmes, GlaxoSmithKline

“Collaborating with Academic Laboratories in Drug Discovery: The GSK Discovery Partnerships with Academia (DPAc) Experience”

Craig Crews, Yale University

“Targeting Protein Degradation”

2:45 pm – 3:00 pm

Refreshment Break

3:00 pm – 4:10 pm
Barbara Slusher and Jonathan Powell, Johns Hopkins University
“Glutamine Antagonists as Novel Targets for Immunotherapy”

Jon de Vlieger, Lygature – The European Lead Factory

“The European Lead Factory – Boosting Collaborative Drug Discovery”

Joseph Wu, Stanford, California Institute for Regenerative Medicine

“iPSCs for Cardiac Disease Modeling, Drug Screening, and Precision Medicine”

4:10 pm – 4:55 pm
KEYNOTE: Bryan Roth, University of North Carolina, Chapel Hill
“Illuminating the Druggable GPCR-ome”

4:55 pm – 5:00 pm

Closing Remarks

5:00 pm – 6:30 pm
Reception and Posters Presentations

Friday, October 13

8:00 am – 2:00 pm
Partnering meetings with Program Directors (by appointment only)


To review abstracts that will be presented during our poster session on Thursday, October 12, download the list of Abstracts in PDF.

Partnering Meetings

October 13, 2017
8:00 am - 2:00 pm

A series of partnering sessions will be held on Friday, October 13, 2017 to enable access to translational Program Directors.

You must be pre-registered to sign up and all appointments are first-come, first-serve. Pre-registrants will be sent a link through which to secure in advance a seat at the small group appointments of interest to them.

Participants Accepting Appointments

Jane B. Acri, Division of Therapeutics and Medical Consequences, NIDA
Addiction Treatment Discovery Program (ATDP), Medication Discovery and Toxicology Branch

The mission of the ATDP is to identify, evaluate, and recommend potential pharmacotherapies as treatments for the medical management of substance use disorders through preclinical testing. Compounds are provided by academia and pharma, and tested at contract sites under blinded conditions to determine if they can reduce drug self-administration, reinstatement, discriminative stimulus effects, locomotor stimulant effects, or produce effects on ICSS or drug withdrawal.

Julian Blagg, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK
Cancer Research UK

Cancer Research UK funds cancer research through a variety of mechanisms, from five research institutes to investigator-led programs and training fellowships. Funding spans the research pipeline, and the CRUK portfolio includes research into a wide variety of types of cancer.

Charles Cywin, NINDS
Division of Translational Research

DTR provides funding and resources (approximately $100 million annually) through grants, cooperative agreements, and contracts to academic and industry researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). DTR offers a variety of programs that support the design, implementation, and management of research activities critical to translational challenges in the treatment of neurological disease.

Kristen P. Doyle, Cancer Prevention & Research Institute of Texas

CPRIT is a $3 billion fund to invest in cancer research and prevention projects in Texas.  CPRIT’s goal is to expedite innovation in cancer research and product development, and to enhance access to evidence-based prevention programs throughout the state.  CPRIT accepts applications and awards peer-reviewed grants for a wide variety of cancer-related research at Texas’ academic institutions and early stage companies  – from basic research to Phase I and II clinical trials.

Martin Duenas, Leidos
OnPAR: A New Funding Paradigm

OnPAR is an initiative from Leidos Life Sciences in partnership with National Institute of Health (NIH) to provide investigators a funding opportunity for their highly scored, unfunded applications. The primary goal of OnPAR is to connect funders with unfunded research applicants. OnPAR matches these unfunded applications with non-government organizations (NGOs). OnPAR members (NGOs) are private foundations, pharmaceuticals, and private funds. This service is free for all investigators worldwide, and investigators do not have to re-write the unfunded application.

Mark Egli, NIAAA
Preclinical Medication Efficacy Testing Program for Alcohol Dependence

NIAAA’s Preclinical Medication Efficacy Testing Program tests proprietary compounds in rodent models of excessive alcohol drinking to evaluate their value for further development for alcohol dependence therapies. Prioritization is given to drugs with a clear development path and to novel pharmacological mechanisms.

Andrew Flint and Barbara Mroczkowski, NCI and Leidos Biomedical Research, Inc.
NCI Experimental Therapeutics Program (NExT)/Chemical Biology Consortium

The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. Applications with exceptional science, a clear path to the clinic and likelihood of providing significant benefit to patients are selected for support by NCI.

The Chemical Biology Consortium (CBC) is the discovery engine of the NExT Program. With 22 centers, it has the drug discovery expertise to advance early stage drug discovery projects from target to identification of clinical candidates.

Francois Franceschi, NIAID
Therapeutic Development Services

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

Duncan Holmes, GlaxoSmithKline
Discovery Partnerships with Academia

Discovery Partnerships with Academia (DPAc) is an innovative approach to drug discovery. As a unit within GSK’s research and development organization, we’re dedicated to creating highly collaborative relationships with leading academic researchers. We believe that working closely together and combining our different strengths is a great way to develop new medicines that truly benefit patients.

Ann Mills-Duggan, Wellcome Trust
Innovator Awards

These awards, of up to £500,000, support researchers who are transforming great ideas into healthcare innovations that could have a significant impact on human health. Our current focus areas are mental health, neurological disorders and neglected tropical diseases, although we may consider applications from other areas.

Aaron Pawlyk, NIDDK
NIDDK Translational Research & Illuminating the Druggable Genome

As part of its mission to reduce the burden of disease, NIDDK participates in a series of funding opportunity announcements to encourage translation of basic discoveries into novel therapeutics.

The goal of the Illuminating the Druggable Genome (IDG) Program is to improve our understanding of the properties and functions of proteins that are currently not well studied within commonly drug-targeted protein families.

Suzana Petanceska, National Institute on Aging
Division of Neuroscience

The Division of Neuroscience (DN) fosters and supports extramural research and training to further the understanding not only the dementias of old age, but also to further an understanding of the neural and behavioral processes associated with the normally aging brain. 

Lorenzo M. Refolo, NIA
Alzheimer’s Drug Development

Preclinical drug discovery and development of novel/repurposed compounds for prevention and treatment of MCI, AD, and other dementias of aging.

Phil Sanderson, NCATS
Therapeutics for Rare and Neglected Diseases; BrIDGs

The NCATS Therapeutics Development Branch has two related programs which provide collaborative, in-kind support for drug development. The programs are intramural and do not provide grant funding.

The Therapeutics for Rare and Neglected Diseases (TRND) program can support late stage discovery and pre-clinical development of drug candidates through Investigational New Drug (IND) application and early clinical development.

The Bridging Interventional Development Gaps (BrIDGs) program assists researchers in advancing drugs through IND enabling studies.

Robert Sons, National Institutes of Health
Tech Transfer Center/Invention Development and Marketing Unit

The mission of NIH includes the application of knowledge to enhance health, lengthen life, and reduce illness and disability. NIH also works with industry to promote technology and economic development. Through partnerships, NIH can leverage its resources with those of industry and, by working together, more effectively apply its knowledge to development of new therapeutics, diagnostics, devices, and digital and wearable health solutions.

Jon de Vlieger, Lygature – The European Lead Factory
The European Lead Factory

The European Lead Factory is a collaborative public-private partnership aiming to deliver innovative drug discovery starting points. Having established the first European Compound Library and the first European Screening Centre, the EU Lead Factory gives free access to up to 500,000 novel compounds, a unique industry-standard uHTS platform, and much more. The initiative is funded through the Innovative Medicines Initiative and at this point has crowdsourced 90 drug targets of which 62 have already progressed through HTS.

Lois Winsky, NIMH
Integrative Systems Pharmacology Program

This program supports interdisciplinary neuroscience research aimed at developing and validating innovative targets and tools to be used in a therapeutic development pipeline for mental illnesses to evaluate targets and to predict clinical effects.

Travel Information


Natcher Conference Center
The ASPET/ADDC Colloquium will be hosted at the Natcher Conference Center (Building 45) on the main campus of the National Institutes of Health (NIH) in Bethesda, MD.

NIH Security
NIH is a government facility and thus subjected to security measures. All attendees must go through security at the NIH Gateway Center.  Visitors will be required go through metal detectors and to show one (1) form of identification (a government-issued photo ID-driver's license, passport, green card, etc.) and to state the purpose of their visit.  Please allow 15 minutes to go through security.

We encourage you to visit NIH Visitor’s information page for additional visitor information.


There are three major airports that service the Washington, D.C. area: Ronald Reagan Washington National Airport (airport code: DCA, 20.8 miles from NIH), Washington Dulles International Airport (airport code: IAD, 27.6 miles from NIH) and Baltimore/Washington International Thurgood Marshall Airport (airport code: BWI, 35.5 miles from NIH).

Amtrak services the area from Washington-Union Station (code: WAS, 11.2 miles from NIH).  The Metrorail red line has stops inside Union Station and on the NIH campus (Medical Center).

The Natcher Conference Center is conveniently accessible via Metrorail’s Red Line, Medical Center stop. 

Visit NIH visitor information to get specific driving directions and parking information.

Visitor parking is available at NIH for $12 per day, however parking is extremely limited.  It is recommended that you take public transportation.


For out of town attendees, we have reserved a block of room at the Bethesda Court Hotel for $189 plus tax a night.  This rate is available until September 11, 2017.

You can make reservation by calling 301-656-2100 or online at  No login or attendee code is required to make online reservations.

Bethesda Court Hotel
7740 Wisconsin Ave, Bethesda, MD 20814
Phone: (301) 656-2100 

The Bethesda Court Hotel is conveniently located 2 blocks away from the Metrorail’s Red Line. You can take the Red Line one stop to the Medical Center stop at NIH.


Interested in sponsoring the Colloquium?

Opportunities are available to partner with ASPET and ADDC to support the Colloquium.  Contact Michael Wood and Matt Hartman at

Gold Level Supporters:

Millipore Sigma
Millipore Sigma

Silver Level Supporters:

Lilly Logo
Lilly (This activity is supported by an educational grant.)

Discovery from Charles River
Charles River





Janssen Research & Development

Waters: The Science of What's Possible

Waters Corporation

Wilson Sonsini Goodrich & Rosati

AbbVie Inc


Job Postings